Alzheimer drug nod won't impact Lupin, Glenmark: Expert

Surajit Pal, analyst, Prabhudas Lilladher continues to have a positive outlook on Glenmark with a target price of Rs 1186 per share.

Pharma major  Lupin and  Glenmark Pharma have received a USFDA nod for an Alzheimer's drug. Surajit Pal, analyst, Prabhudas Lilladher believes the same won't have too much impact on either company.

Pal continues to have a positive outlook on Glenmark with a target price of Rs 1186 per share.

Watch video for more.

Anda sedang membaca artikel tentang

Alzheimer drug nod won't impact Lupin, Glenmark: Expert

Dengan url

https://segarsaries.blogspot.com/2015/04/alzheimer-drug-nod-wont-impact-lupin.html

Anda boleh menyebar luaskannya atau mengcopy paste-nya

Alzheimer drug nod won't impact Lupin, Glenmark: Expert

namun jangan lupa untuk meletakkan link

Alzheimer drug nod won't impact Lupin, Glenmark: Expert

sebagai sumbernya